Abstract |
KY02111 is a widely used small molecule that boosts cardiomyogenesis of the mesoderm cells derived from pluripotent stem cells, yet its molecular mechanism of action remains elusive. The present study resolves the initially perplexing effects of KY02111 on Wnt signaling and subsequently identifies squalene synthase (SQS) as a molecular target of KY02111 and its optimized version, KY-I. By disrupting the interaction of SQS with cardiac ER- membrane protein TMEM43, KY02111 impairs TGFβ signaling, but not Wnt signaling, and thereby recapitulates the clinical mutation of TMEM43 that causes arrhythmogenic right ventricular cardiomyopathy (ARVC), an inherited heart disease that involves a substitution of myocardium with fatty tissue. These findings reveal a heretofore undescribed role of SQS in TGFβ signaling and cardiomyogenesis. KY02111 may find its use in ARVC modeling as well as serve as a chemical tool for studying TGFβ/SMAD signaling.
|
Authors | Yasushi Takemoto, Shin Kadota, Itsunari Minami, Shinya Otsuka, Satoshi Okuda, Masahiro Abo, Louvy Lynn Punzalan, Yan Shen, Yuji Shiba, Motonari Uesugi |
Journal | Angewandte Chemie (International ed. in English)
(Angew Chem Int Ed Engl)
Vol. 60
Issue 40
Pg. 21824-21831
(09 27 2021)
ISSN: 1521-3773 [Electronic] Germany |
PMID | 34374184
(Publication Type: Journal Article, Research Support, Non-U.S. Gov't)
|
Copyright | © 2021 Wiley-VCH GmbH. |
Chemical References |
- Benzothiazoles
- Enzyme Inhibitors
- KY02111
- Phenylpropionates
- Transforming Growth Factor beta
- Farnesyl-Diphosphate Farnesyltransferase
|
Topics |
- Benzothiazoles
(chemistry, pharmacology)
- Enzyme Inhibitors
(chemistry, pharmacology)
- Farnesyl-Diphosphate Farnesyltransferase
(antagonists & inhibitors, metabolism)
- Humans
- Molecular Structure
- Myocardium
(metabolism)
- Phenylpropionates
(chemistry, pharmacology)
- Signal Transduction
(drug effects)
- Transforming Growth Factor beta
(antagonists & inhibitors, metabolism)
|